---
title: "Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280483753.md"
description: "Novo Nordisk's UBT251 has shown superior results in a phase 2 trial in China, outperforming semaglutide in reducing blood sugar and weight. The trial revealed a 2.16% reduction in HbA1c levels and up to 9.8% weight loss with UBT251, compared to 1.77% and 4.8% for semaglutide, respectively. The drug targets GLP-1, GIP, and glucagon receptors and is co-developed with United Bio-Technology. Novo Nordisk plans further global trials, with detailed results to be presented at an upcoming medical conference. NVO shares rose 0.89% to $37.22."
datetime: "2026-03-25T13:36:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280483753.md)
  - [en](https://longbridge.com/en/news/280483753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280483753.md)
---

# Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

**The United Laboratories International Holdings Limited** and **Novo Nordisk A/S** (NYSE:NVO) reported Wednesday topline data from a phase 2 trial in China showing that UBT251, a triple receptor agonist.

Semaglutide is a key ingredient in the famed Wegovy and Ozempic.

UBT251 is designed to challenge **Eli Lilly & Co.'s** (NYSE:LLY) ‘Triple G' obesity drug, retatrutide, which has already shown promising weight loss results.

## UBT251 Shows Superior Glycemic Control And Weight Loss

The once-weekly injectable UBT251 targets GLP-1, GIP, and glucagon receptors, positioning it within a growing class of multi-agonist therapies. The candidate is being co-developed by United Bio-Technology and Novo Nordisk under a March 2025 agreement.

Under the collaboration, United Biotechnology leads development across mainland China, Hong Kong, Macau, and Taiwan, while Novo Nordisk oversees global markets.

In the 24-week study, patients receiving UBT251 achieved a maximum mean HbA1c (blood sugar) reduction of 2.16% from a baseline of 8.12%.

This compares with a 1.77% reduction for semaglutide 1 mg and 0.66% for placebo.

Weight loss outcomes also favored UBT251.

From a baseline weight of 80.1 kg, patients saw reductions of up to 9.8%, versus 4.8% with semaglutide and 1.4% with placebo.

## Improvements Across Secondary Endpoints

Beyond glycemic control and weight, UBT251 demonstrated improvements in waist circumference, blood pressure and lipid levels compared with placebo.

The safety and tolerability profile was consistent with prior studies of triple agonists, with no unexpected findings reported.

## Next Steps: Global Trials And Phase 3 Plans

Novo Nordisk has already initiated a global phase 1b/2a trial evaluating UBT251 in overweight participants, with results expected in 2027.

The company plans to begin a global phase 2 trial in type 2 diabetes in the second half of 2026.

United Biotechnology intends to advance the program locally, with plans to launch two phase 3 trials in Chinese patients.

Detailed data from the current study will be presented at a medical conference later this year.

**NVO Stock Price Activity:** Novo Nordisk shares were up 0.89% at $37.22 at the last check on Wednesday, according to Benzinga Pro data.

_Image via Shutterstock_

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [03933.HK](https://longbridge.com/en/quote/03933.HK.md)

## Related News & Research

- [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md)
- [Novo Nordisk Highlights New Wegovy Pill Data](https://longbridge.com/en/news/286293294.md)
- [Are Wall Street Analysts Predicting Brown-Forman Stock Will Climb or Sink?](https://longbridge.com/en/news/286932286.md)
- [CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs](https://longbridge.com/en/news/286925029.md)
- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)